ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.943,73
-0,44%
S&P 500
5.299,00
1,00%
US Dollar vs BRL
5,1413
0,23%
Bitcoin
65.328,76
6,14%
Brent Oil
82,595
0,05%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Deciphera Pharmaceuticals Inc (DCPH)

  7. Deciphera Pharmaceuticals Inc (DCPH) Notícias

DCPH

Deciphera Pharmaceuticals (DCPH)

Deciphera Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:DCPH
DataHoraFonteTítuloCódigoCompanhia
13/05/202407:32Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
13/05/202407:31Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
10/05/202408:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/05/202418:16Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/04/202408:00Business WireDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionNASDAQ:DCPHDeciphera Pharmaceuticals Inc
09/04/202408:00Business WireDeciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
27/02/202409:00Business WireDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
20/02/202418:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
14/02/202418:06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202409:52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202409:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/02/202409:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/02/202409:00Business WireDeciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202418:50Business WireDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024NASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202409:00Business WireDeciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
18/01/202413:13Business WireDeciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
08/01/202409:00Business WireDeciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product CompanyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
05/01/202409:00Business WireDeciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18NASDAQ:DCPHDeciphera Pharmaceuticals Inc
02/01/202409:00Business WireDeciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/11/202320:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/11/202309:00Business WireDeciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology SummitNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202308:01Business WireDeciphera Pharmaceuticals Announces Third Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202308:00Business WireDeciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCTNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/09/202310:00PR Newswire (Canada)Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) TreatmentNASDAQ:DCPHDeciphera Pharmaceuticals Inc
15/09/202318:00Business WireDeciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
05/09/202317:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
09/08/202308:00Business WireDeciphera Pharmaceuticals Announces Second Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
03/08/202317:15Business WireDeciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific OfficerNASDAQ:DCPHDeciphera Pharmaceuticals Inc
02/08/202308:00Business WireDeciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023NASDAQ:DCPHDeciphera Pharmaceuticals Inc
23/06/202317:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:DCPH

Seu Histórico Recente

COIN
WEEDGBP
BIT
UV8B7K
UniCredit Bank
UNSW3
XLABETH
XCELTOKEN PLUS
LSE
70TD
Br.tel.6.375%
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados